person · Reporting owner
Farley Chele Chiavacci
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CDT Equity Inc.CDT · Entity 1035 | Director | February 19, 2026 | February 24, 2026 |
| General Purpose Acquisition Corp.GPAC · Entity 5958 | Director | December 02, 2025 | December 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CDT Equity Inc.
Report date February 19, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,157 |
Reported balance
After 2026-02-19 transaction · row 1
1 source rowRow 1 · 2026-02-19 · Grant · Acquired 10,553 · Balance 17,157 F1: On February 19, 2026, CDT Equity Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with the reporting person and other stockholders (the "Investors") of Sarborg Limited, a Cayman Islands Company ("Sarborg"), pursuant to which the reporting person agreed to sell to the Company, and the Company agreed to acquire from the reporting person, 18 shares of Sarborg having an aggregate value of approximately $2,029,411 in exchange for (i) 10,553 shares of the Company's Common Stock, and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 1,940,804 shares of the Company's Common Stock, reflecting a purchase price of $1.04 per share. |
| Pre-Funded WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,940,804 |
Reported balance
After 2026-02-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-19 · Grant · Acquired 1,940,804 · Balance 1,940,804 F1: On February 19, 2026, CDT Equity Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with the reporting person and other stockholders (the "Investors") of Sarborg Limited, a Cayman Islands Company ("Sarborg"), pursuant to which the reporting person agreed to sell to the Company, and the Company agreed to acquire from the reporting person, 18 shares of Sarborg having an aggregate value of approximately $2,029,411 in exchange for (i) 10,553 shares of the Company's Common Stock, and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 1,940,804 shares of the Company's Common Stock, reflecting a purchase price of $1.04 per share. F2: The Pre-Funded Warrants may not be exercised until the Company obtains requisite stockholder approval in accordance with Nasdaq Listing Rule 5635. F3: The Pre-Funded Warrants will remain exercisable until all Pre-Funded Warrants are exercised in full. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 19, 2026, CDT Equity Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with the reporting person and other stockholders (the "Investors") of Sarborg Limited, a Cayman Islands Company ("Sarborg"), pursuant to which the reporting person agreed to sell to the Company, and the Company agreed to acquire from the reporting person, 18 shares of Sarborg having an aggregate value of approximately $2,029,411 in exchange for (i) 10,553 shares of the Company's Common Stock, and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 1,940,804 shares of the Company's Common Stock, reflecting a purchase price of $1.04 per share.
F2: The Pre-Funded Warrants may not be exercised until the Company obtains requisite stockholder approval in accordance with Nasdaq Listing Rule 5635.
F3: The Pre-Funded Warrants will remain exercisable until all Pre-Funded Warrants are exercised in full.
General Purpose Acquisition Corp.
Report date December 02, 2025 · Filed December 02, 2025
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2026 Filed Feb 24, 2026 01:27 UTC | CDT Equity Inc. CDT · Entity 1035 | GrantPre-Funded Warrants · Derivative | 1,940,804 | $1.04 Strike: $0.00 | $2,018,436.16 |
DisclosureSEC source: 0001493152-26-007794 · ownership.xml · derivative · entry 2 Farley Chele Chiavacci · CIK 0001908750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,940,804 Underlying: Common Stock · 1,940,804 shares Expires not disclosed F1 · price: On February 19, 2026, CDT Equity Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with the reporting person and other stockholders (the "Investors") of Sarborg Limited, a Cayman Islands Company ("Sarborg"), pursuant to which the reporting person agreed to sell to the Company, and the Company agreed to acquire from the reporting person, 18 shares of Sarborg having an aggregate value of approximately $2,029,411 in exchange for (i) 10,553 shares of the Company's Common Stock, and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 1,940,804 shares of the Company's Common Stock, reflecting a purchase price of $1.04 per share. F2 · derivative.exercise_date: The Pre-Funded Warrants may not be exercised until the Company obtains requisite stockholder approval in accordance with Nasdaq Listing Rule 5635. F3 · derivative.expiration_date: The Pre-Funded Warrants will remain exercisable until all Pre-Funded Warrants are exercised in full. Read SEC document |
| February 19, 2026 Filed Feb 24, 2026 01:27 UTC | CDT Equity Inc. CDT · Entity 1035 | GrantCommon Stock | 10,553 | $1.04 | $10,975.12 |
DisclosureSEC source: 0001493152-26-007794 · ownership.xml · nonDerivative · entry 1 Farley Chele Chiavacci · CIK 0001908750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,157 F1 · shares: On February 19, 2026, CDT Equity Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with the reporting person and other stockholders (the "Investors") of Sarborg Limited, a Cayman Islands Company ("Sarborg"), pursuant to which the reporting person agreed to sell to the Company, and the Company agreed to acquire from the reporting person, 18 shares of Sarborg having an aggregate value of approximately $2,029,411 in exchange for (i) 10,553 shares of the Company's Common Stock, and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 1,940,804 shares of the Company's Common Stock, reflecting a purchase price of $1.04 per share. Read SEC document |
| August 12, 2025 Filed Aug 26, 2025 20:30 UTC | CDT Equity Inc. CDT · Entity 1035 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-025538 · ownership.xml · nonDerivative · entry 1 Farley Chele Chiavacci · CIK 0001908750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,369 F1 · shares: Represents restricted stock units ("RSUs") received on August 12, 2025, in exchange for past services, having a value equal to approximately $60,900 based on the closing price per share of the Issuer's common stock on August 12, 2025. The RSUs vest immediately upon grant. Read SEC document |
| August 05, 2025 Filed Aug 26, 2025 20:30 UTC | CDT Equity Inc. CDT · Entity 1035 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001641172-25-025538 · ownership.xml · derivative · entry 2 Farley Chele Chiavacci · CIK 0001908750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-08-05 F2 · security: Represents options to purchase common stock, granted under the Issuer's 2023 Stock Incentive Plan, which were granted at the conclusion of the Issuer's 2025 annual meeting of stockholders. F3 · derivative.exercise_date: The options vest immediately upon grant. Read SEC document |
| March 30, 2025 Filed Apr 2, 2025 01:07 UTC | CDT Equity Inc. CDT · Entity 1035 | GrantCommon Stock | 32,022 | $0.89 | $28,499.58 |
DisclosureSEC source: 0001641172-25-002236 · ownership.xml · nonDerivative · entry 1 Farley Chele Chiavacci · CIK 0001908750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,537 F1 · shares: Represents shares issued pursuant to the 2023 Stock Incentive Plan, in lieu of $28,500 accrued in cash retainers under the Issuer's Non-Employee Director Compensation Program. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 22:06 UTC | CDT Equity Inc. CDT · Entity 1035 | GrantStock Option (Right to Buy) · Derivative | 420,000 | $0.07 Strike: $0.07 | $29,820.00 |
DisclosureSEC source: 0001493152-24-051098 · ownership.xml · derivative · entry 1 Farley Chele Chiavacci · CIK 0001908750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 420,000 Underlying: Common Stock · 420,000 shares Expires 2034-12-18 F1 · security: Represents options to purchase common stock, granted under the Issuer's 2023 Stock Incentive Plan, which were granted at the conclusion of the Issuer's 2024 annual meeting of stockholders. F2 · derivative.exercise_date: The options will vest on the earlier of (x) the first anniversary of the date of grant, or (y) the date immediately prior to the next annual meeting of the Issuer's stockholders following the date of grant. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 21:30 UTC | CDT Equity Inc. CDT · Entity 1035 | GrantCommon Stock | 299,238 | $0.09 | $27,499.97 |
DisclosureSEC source: 0001493152-24-046992 · ownership.xml · nonDerivative · entry 1 Farley Chele Chiavacci · CIK 0001908750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,510 F1 · shares: Represents shares issued in lieu of $27,500 accrued in cash retainers under the Issuer's Non-Employee Director Compensation Program. Read SEC document |
| June 11, 2024 Filed Jun 11, 2024 21:56 UTC | CDT Equity Inc. CDT · Entity 1035 | GrantCommon Stock | 37,272 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-023518 · ownership.xml · nonDerivative · entry 1 Farley Chele Chiavacci · CIK 0001908750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,272 F1 · price: The shares have a value in excess of the par value of the company's shares and are fully vested (fully paid and nonassessable) as of June 11, 2024. Read SEC document |
| April 22, 2024 Filed Apr 24, 2024 21:00 UTC | CDT Equity Inc. CDT · Entity 1035 | PurchaseWarrant (Right to buy) · Derivative | 200,332 | Not disclosed Strike: $3.12 | Not disclosed |
DisclosureSEC source: 0001493152-24-015814 · ownership.xml · derivative · entry 2 Farley Chele Chiavacci · CIK 0001908750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,332 Underlying: Common Stock · 200,332 shares Expires 2027-04-22 F2 · security: Warrants purchased in exchange for $0.25 per warrant in private transaction. F2 · price: Warrants purchased in exchange for $0.25 per warrant in private transaction. Read SEC document |
| April 22, 2024 Filed Apr 24, 2024 21:00 UTC | CDT Equity Inc. CDT · Entity 1035 | GrantWarrant (Right to buy) · Derivative | 3,000 | Not disclosed Strike: $3.12 | Not disclosed |
DisclosureSEC source: 0001493152-24-015814 · ownership.xml · derivative · entry 1 Farley Chele Chiavacci · CIK 0001908750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2027-04-22 F1 · security: Warrants issued in exchange for one year lock-up of reporting person's common stock of the company, par value $0.0001 per share, and the payment of $0.125 per warrant. F1 · price: Warrants issued in exchange for one year lock-up of reporting person's common stock of the company, par value $0.0001 per share, and the payment of $0.125 per warrant. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 22:20 UTC | CDT Equity Inc. CDT · Entity 1035 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $5.51 Strike: $5.51 | $358,150.00 |
DisclosureSEC source: 0001493152-23-043747 · ownership.xml · derivative · entry 1 Farley Chele Chiavacci · CIK 0001908750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2033-11-30 F1 · security: Represents Options to purchase common stock, granted under the Company's 2023 Stock Incentive Plan. F2 · derivative.exercise_date: The stock options were granted with a ten-year term and vest 33.3% on each of the first three anniversaries of the vesting commencement date, which is September 22, 2023. Read SEC document |
| September 22, 2023 Filed Sep 26, 2023 21:49 UTC | CDT Equity Inc. CDT · Entity 1035 | GrantWarrants · Derivative | 15,000 | $11.50 Strike: $11.50 | $172,500.00 |
DisclosureSEC source: 0001493152-23-033793 · ownership.xml · derivative · entry 2 Farley Chele Chiavacci · CIK 0001908750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Shares · 15,000 shares Expires 2028-10-22 F2 · derivative.exercise_date: The redeemable warrants become exercisable 30 days after the completion of the business combination contemplated by the Merger Agreement, which occurred on September 22, 2023. Accordingly, the redeemable warrants become exercisable on October 22, 2023 and expire on October 22, 2028. Read SEC document |
| September 22, 2023 Filed Sep 26, 2023 21:49 UTC | CDT Equity Inc. CDT · Entity 1035 | GrantCommon Stock, par value $0.0001 per share ("Shares") | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-033793 · ownership.xml · nonDerivative · entry 1 Farley Chele Chiavacci · CIK 0001908750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Includes 15,000 shares of common stock of the Company and 15,000 redeemable warrants that Murphy Canyon Acquisition Sponsor, LLC transferred to Ms. Farley in consideration for her acting as an independent director of the Company. Such Shares and warrants were transferred to Mr. Farley immediately after the closing of the business combination contemplated by the Agreement and Plan of Merger, dated as of November 8, 2022 and as amended on January 27, 2023 and May 11, 2023 (the "Merger Agreement"), by and among the Company, Conduit Pharmaceuticals Limited, a Cayman Islands exempted company ("Conduit") and Conduit Merger Sub, Inc., a Cayman Islands exempted company and a wholly-owned subsidiary of MURF (the "Merger Sub"). As a result of, and upon consummation of the transactions contemplated by, the Merger Agreement, the Company changed its name from "Murphy Canyon Acquisition Corp." to "Conduit Pharmaceuticals Inc." F1 · price: Includes 15,000 shares of common stock of the Company and 15,000 redeemable warrants that Murphy Canyon Acquisition Sponsor, LLC transferred to Ms. Farley in consideration for her acting as an independent director of the Company. Such Shares and warrants were transferred to Mr. Farley immediately after the closing of the business combination contemplated by the Agreement and Plan of Merger, dated as of November 8, 2022 and as amended on January 27, 2023 and May 11, 2023 (the "Merger Agreement"), by and among the Company, Conduit Pharmaceuticals Limited, a Cayman Islands exempted company ("Conduit") and Conduit Merger Sub, Inc., a Cayman Islands exempted company and a wholly-owned subsidiary of MURF (the "Merger Sub"). As a result of, and upon consummation of the transactions contemplated by, the Merger Agreement, the Company changed its name from "Murphy Canyon Acquisition Corp." to "Conduit Pharmaceuticals Inc." Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.